ARCHIVES

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

This article is from The Cancer Letter archive.

Vol. 33 No. 18 | May 11, 2007

Download PDF Visit The Full Archive

Related Articles

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

November 2, 2007

FDA Proposes Office For Patients With Life Threatening Disease

November 13, 1992

Funding Opportunities: NCI Grant Supplements For Mammalian Models

October 22, 1999

Nominations Open for Bristol-Myers $25,000

September 29, 1978

Adherez Issued U.S. Patent for Catenin Molecule Inhibition.

July 4, 2003

DCCP Recompetitions Approved Board Asks Others At NIH To Help Pay For Some Resources

October 24, 1980